NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00886587,To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children,https://clinicaltrials.gov/study/NCT00886587,,COMPLETED,"The purpose of this study was to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in comparison to that of a similar marketed product. This study was conducted to assess the safety of the investigational new study product and how well it works to treat AD in children, by making AD visually better, and reducing the amount of itch.",YES,Atopic Dermatitis,DEVICE: F# 11054-010|DEVICE: F# 10495-053,"Eczema Area and Severity Index (EASI) Score on Day 43 - Change From Baseline, The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI). A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final possible calculation ranging from 0 (none) - 72 (severe)., Baseline to Day 43","Eczema Area and Severity Index (EASI) on Day 15 - Change From Baseline, The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI). A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final possible calculation ranging from 0 (none) - 72 (severe)., Baseline to Day 15|Investigator's Global Atopic Dermatitis Assessment (IGADA) on Day 43 - Change From Baseline, The signs and symptoms of eczema are measured using the Investigator's Global Atopic Dermatitis Assessment (IGADA), with possible values of clear (0), almost clear (1), mild (2), moderate (3), severe (4), or very severe (5)., Baseline to Day 43|Itch Score on Day 43 - Change From Baseline, The subject's and/or caregiver's assessment of itch was measured on a 10-cm visual analog scale (VAS) in which 0 cm represented no itch and 10 cm represented worst itch imaginable., Baseline to Day 43",,Johnson & Johnson Consumer and Personal Products Worldwide,,ALL,CHILD,NA,82,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",EMOECZ0002,2009-04,2009-06,2009-06,2009-04-23,2017-01-16,2017-05-23,"Thomas J. Stephens & Associates, Inc, Colorado Springs, Colorado, 80915, United States|Academic Dermatology Associates, Albuquerque, New Mexico, 87106, United States",
